Section Arrow
Quote
AUPH.NASDAQ
- Aurinia Pharmaceuticals
Quotes are at least 15-min delayed:2025/08/31 22:39 EDT
Regular Hours
Last
 11.99
-0.09 (-0.75%)
Day High 
12.16 
Prev. Close
12.08 
1-M High
12.53 
Volume 
806.09K 
Bid
11.9
Ask
12.16
Day Low
11.93 
Open
12.15 
1-M Low
8.8 
Market Cap 
1.59B 
Currency USD 
P/E 28.09 
%Yield -- 
10-SMA 12.14 
20-SMA 11.82 
50-SMA 9.82 
52-W High 12.53 
52-W Low 6.42 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.43/0.90
Enterprise Value
1.65B
Balance Sheet
Book Value Per Share
2.55
Cash Flow
Cash Flow Yield
0.05
Income Statement
Total Revenue
235.13M
Operating Revenue Per Share
1.21
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.215-0.013-5.70%-- 
TNFATNF Pharmaceuticals Inc.0.0483-0.0133-21.59%-- 
ADAPAdaptimmune Therapeutics plc0.0589-0.01-14.51%-- 
SRPTSarepta Therapeutics18.2-0.14-0.76%15.76PE
OTLKOutlook Therapeutics0.8512-0.2388-21.91%0.58PE
Quotes are at least 15-min delayed：2025/08/31 22:39 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmunediseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.